Cytotoxic activity of CD4+ T cells against autologous tumor cells. 1995

Y Konomi, and T Sekine, and T Takayama, and M Fuji, and T Tanaka
RI Laboratory, National Cancer Center Research Institute, Tokyo.

The 51Cr-release assay is mostly applied to detecting the cytotoxic activity of CD8+ T cells, and little is known about the activity of CD4+ T cells. Therefore, the correlation between the cytotoxic activity of CD4+ or CD8+ T cells and the incubation period with autologous tumor cells was analyzed by two methods. The incubation periods were 4 and 20 h (4 h and 20 h assay) for the 51Cr-release assay. Eight pairs of tumor cells and T cells were assayed. T cells were fractionated into CD4+ and CD8+ T cells by using magnetic beads and panning methods, and those cells were activated by culture with recombinant interleukin-2 and immobilized anti-CD3 monoclonal antibody. In 6 out of 8 cases, no cytotoxic activity of CD4+ T cells was detected by the 4 h assay, whereas cytotoxic activity was detected in all cases in the 20 h assay. The cytotoxic activities in 20 h assay of CD4+ T cells were increased 67-fold in comparison with the activities in 4 h assay (range: 5-197). In the case of CD8+ T cells, cytotoxic activities were detected in 6 out of 8 cases in the 4 h assay. The lytic unit ratio of CD4+ and CD8+ T cells was calculated as 1.5 in the 20 h assay (range: 0.2- > 7.2) versus 0.4 in the 4 h assay (range: < 0.1-1.3). Cytotoxic activities in colorimetric assay using Crystal Violet with a 24 h incubation were similar to those in the 20 h 51Cr-release assay in all eight cases. These results indicate that CD4+ T cells have cytotoxic activity as strong as that of CD8+ T cells towards autologous tumor cells.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002857 Chromium A trace element that plays a role in glucose metabolism. It has the atomic symbol Cr, atomic number 24, and atomic weight 52. According to the Fourth Annual Report on Carcinogens (NTP85-002,1985), chromium and some of its compounds have been listed as known carcinogens.
D002860 Chromium Radioisotopes Unstable isotopes of chromium that decay or disintegrate emitting radiation. Cr atoms with atomic weights of 46-49, 51, 55, and 56 are radioactive chromium isotopes. Radioisotopes, Chromium
D003124 Colorimetry Any technique by which an unknown color is evaluated in terms of standard colors. The technique may be visual, photoelectric, or indirect by means of spectrophotometry. It is used in chemistry and physics. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D005260 Female Females
D005840 Gentian Violet A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties. Crystal Violet,Methyl Violet,Methylrosaniline Chloride,C.I. 42555,Gentiaanviolet FNA,Hexamethylpararosaniline Chloride,Kristallviolett-Lösung,Vigencial,Chloride, Hexamethylpararosaniline,Chloride, Methylrosaniline,FNA, Gentiaanviolet,Kristallviolett Lösung,Violet, Crystal,Violet, Gentian,Violet, Methyl
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Y Konomi, and T Sekine, and T Takayama, and M Fuji, and T Tanaka
April 2000, Journal of immunology (Baltimore, Md. : 1950),
Y Konomi, and T Sekine, and T Takayama, and M Fuji, and T Tanaka
February 2013, Cancer immunology, immunotherapy : CII,
Y Konomi, and T Sekine, and T Takayama, and M Fuji, and T Tanaka
January 2022, Frontiers in immunology,
Y Konomi, and T Sekine, and T Takayama, and M Fuji, and T Tanaka
January 2021, Clinical & translational immunology,
Y Konomi, and T Sekine, and T Takayama, and M Fuji, and T Tanaka
August 1975, Zeitschrift fur Immunitatsforschung, experimentelle und klinische Immunologie,
Y Konomi, and T Sekine, and T Takayama, and M Fuji, and T Tanaka
June 2008, Current opinion in immunology,
Y Konomi, and T Sekine, and T Takayama, and M Fuji, and T Tanaka
October 1992, Journal of immunological methods,
Y Konomi, and T Sekine, and T Takayama, and M Fuji, and T Tanaka
March 1998, Cytotechnology,
Y Konomi, and T Sekine, and T Takayama, and M Fuji, and T Tanaka
March 2023, BMB reports,
Y Konomi, and T Sekine, and T Takayama, and M Fuji, and T Tanaka
April 1984, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Copied contents to your clipboard!